Skip to main content

Early value dossiers for medical technologies

The essential tool to understand the value proposition for your product and position it well with reimbursement/HTA stakeholders

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Publication Digest: A systematic review of the early dialogue frameworks used within health technology assessment and their actual adoption from HTA agencies

03 Apr 2023

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Publications Digest. In a recent publication, Ibargoyen-Roteta et al. summarized the main initiatives in relation to Early Dialogue/Scientific Advice/Early Advice given by international HTA bodies to manufacturers of medical technologies. In relation to medical technologies, the authors reviewed early dialogue frameworks of NICE (UK), Health Technology Wales and HAS (France).

Access the full-text article here.